Archives
ASH: Ibrutinib-Venetoclax Beneficial for Relapsed/Refractory Lymphoma
Improvement seen in progression-free survival for patients with relapsed/refractory mantle cell lymphoma
ASH: MRD-Directed Ibrutinib-Venetoclax Treatment Beneficial in Leukemia
Improvement in survival seen with measurable residual disease-directed ibrutinib-venetoclax versus fludarabine-cyclophosphamide-rituximab
ChatGPT Shows Poor Performance in Answering Drug-Related Questions
Nearly three-quarters of drug-related questions received no response or incomplete, wrong answers
ASH: Axi-Cel CAR T-Cell Treatment Effective in High-Risk Lymphoma Patients
Five-year PFS was 28.5 percent and overall survival was 40.3 percent; 40.2 percent of patients did not meet ZUMA-1 eligibility criteria
SABCS: Serum Hormones Can Help ID Benefit of Anastrozole
Women in quartiles 2, 3, and 4 of the estradiol-SHBG ratio demonstrated a relative benefit of anastrozole
SABCS: 22 Percent of Young BRCA Carriers Conceive After Breast Cancer
No significant difference seen in disease-free survival for those with, without pregnancy; overall survival up for those with pregnancy
Withholding Intubation Helpful for Comatose Patients With Acute Poisoning
Benefits seen for composite of in-hospital death and length of intensive care unit and hospital stay
SABCS: Outcomes No Worse for Survivors With Less Frequent Mammograms
Breast cancer-specific survival at five years noninferior with less frequent mammograms versus annual mammograms
SABCS: Positive Outcomes Seen When Pausing Endocrine Therapy to Become Pregnant
Incidence of breast cancer-free interval events similar for those undergoing ovarian stimulation for cryopreservation or not
SABCS: Neoadjuvant Chemo Can Let Breast Cancer Patients Skip Nodal RT
Skipping adjuvant regional nodal irradiation does not increase risk for recurrence or death after neoadjuvant chemo before breast-conserving surgery
